Security
ImmuCell Corporation Common Stock · ICCC
ICCCNASDAQCommon stockCurrentCIK 811641Updated Oct 14, 2026
ICCC price & chart
Loading TradingView…
NASDAQ:ICCC on TradingView ↗About the company
ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
In the news
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026 ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
10-K/A filing
Entry into a Material Definitive Agreement
Items 1.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 42,532,447Source | 45,100,477Source | 43,808,102Source | 44,860,649Source |
| Property, Plant and Equipment, NetUSD | 21,074,694Source | 25,349,019Source | 27,575,683Source | 28,441,726Source |
| GoodwillUSD | 95,557Source | 95,557Source | 95,557Source | 95,557Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | 57,312Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,806,831Source | — | 978,741Source | 5,791,562Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,419,009Source | 3,771,133Source | 2,185,383Source | 1,758,600Source |
| Inventory, NetUSD | 9,267,369Source | 7,112,623Source | 7,811,841Source | 6,038,539Source |
| Assets, CurrentUSD | 16,944,882Source | 15,042,750Source | — | 13,994,756Source |
| Prepaid Expense and Other Assets, CurrentUSD | 451,673Source | 400,762Source | 493,885Source | 406,055Source |
| Operating Lease, Right-of-Use AssetUSD | 4,379,628Source | 4,560,679Source | 4,571,149Source | 2,194,670Source |
| Other Assets, NoncurrentUSD | 37,686Source | 33,368Source | 11,469,850Source | 76,628Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 15,476,967Source | 17,582,290Source | 18,815,025Source | 14,480,600Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 910,563Source | 904,240Source | 781,417Source | 781,417Source |
| Additional Paid in CapitalUSD | — | — | — | 35,978,364Source |
| Retained Earnings (Accumulated Deficit)USD | -15,203,753Source | -14,163,726Source | -12,007,097Source | -6,232,499Source |
| Stockholders' Equity Attributable to ParentUSD | 27,055,480Source | 27,518,187Source | 24,993,077Source | 30,380,049Source |
| Additional Paid in Capital, Common StockUSD | 41,479,430Source | 40,916,155Source | 36,357,239Source | — |
| Liabilities and EquityUSD | 42,532,447Source | 45,100,477Source | 43,808,102Source | 44,860,649Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,978,257Source | 4,412,213Source | 4,197,420Source | 3,072,073Source |
| Operating Lease, Liability, CurrentUSD | 85,489Source | 432,072Source | 644,276Source | 31,764Source |
| Operating Lease, Liability, NoncurrentUSD | 4,009,788Source | 4,129,102Source | 4,077,109Source | 2,217,418Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | 1,758,600Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 10,230,556Source |
| Long-term Debt, Current MaturitiesUSD | 1,610,185Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 7,488,922Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,783,949Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 295,871Source | 325,551Source | 368,866Source | 266,244Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -352,124Source | 1,585,750Source | 426,783Source | — |
| Increase (Decrease) in InventoriesUSD | 2,154,746Source | -699,218Source | 1,773,302Source | 2,948,565Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | 7,672Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 2,475,292Source | 357,903Source | -4,674,236Source | -1,543,871Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,214,307Source | -461,225Source | -1,890,039Source | -3,964,274Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,250,439Source | 465,725Source | 1,892,513Source | 3,975,274Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -1,212,386Source | 2,882,813Source | 1,751,454Source | 1,114,239Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 48,599Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 3,758,232Source | 978,741Source | 5,791,562Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 443,019Source | 528,907Source | 444,954Source | 338,516Source |
| Income Taxes Paid, NetUSD | 10,691Source | — | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | — | — | — | 19,104Source |
| Share-based Payment Arrangement, ExpenseUSD | 295,871Source | 325,551Source | 368,866Source | 266,244Source |
| Amortization of Debt Issuance CostsUSD | — | 42,666Source | 13,072Source | 7,658Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 54,348Source | 42,666Source | 22,619Source | — |
| Amortization of Intangible AssetsUSD | 19,104Source | 19,104Source | 19,104Source | 19,104Source |
| Deferred Other Tax Expense (Benefit)USD | 332,646Source | 559,959Source | 1,325,276Source | — |
| DepreciationUSD | 2,710,497Source | 2,668,077Source | 2,697,897Source | 2,468,479Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | 15,391Source | -8,099Source | 7,334Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -106,350Source | -15,391Source | -8,099Source | — |
| General and Administrative ExpenseUSD | 3,200,643Source | 2,216,549Source | 2,134,295Source | 2,263,817Source |
| GoodwillUSD | 95,557Source | 95,557Source | 95,557Source | 95,557Source |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Income Tax Expense (Benefit)USD | 11,570Source | 10,056Source | 4,627Source | 7,672Source |
| InterestExpenseNonoperatingUSD | 493,384Source | — | — | — |
| Inventory Write-downUSD | — | 406,565Source | 527,133Source | — |
| Investment Income, InterestUSD | 158,709Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -1,040,027Source | -2,156,629Source | -5,774,598Source | -2,493,805Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | -2,493,805Source |
| Nonoperating Income (Expense)USD | -2,677,762Source | -506,414Source | — | — |
| Operating ExpensesUSD | 9,795,898Source | 9,581,203Source | 9,617,362Source | 9,947,722Source |
| Other Nonoperating Income (Expense)USD | — | — | -21,893Source | -187,190Source |
| Other Operating Income (Expense), NetUSD | — | — | — | 187,190Source |
| Proceeds from Issuance of Common StockUSD | 349,326Source | 4,648,022Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 3Source | — | 18,760Source | 30,670Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 26,493,169Source | 17,471,669Source | 18,567,962Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 27,644,174Source | 26,493,169Source | 17,471,669Source | 18,567,962Source |
| Cost of RevenueUSD | — | 18,552,125Source | 13,602,385Source | 10,919,183Source |
| Operating Income (Loss)USD | 1,649,305Source | -1,640,159Source | -5,748,078Source | -2,298,943Source |
| Other Nonoperating Income (Expense)USD | — | — | -21,893Source | -187,190Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,028,457Source | -2,146,573Source | -5,769,971Source | -2,486,133Source |
| Income Tax Expense (Benefit)USD | 11,570Source | 10,056Source | 4,627Source | 7,672Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | -2,493,805Source |
| Net Income (Loss) Attributable to ParentUSD | -1,040,027Source | -2,156,629Source | -5,774,598Source | -2,493,805Source |
| Earnings Per Share, BasicUSD per share | -0.12Source | -0.26Source | -0.75Source | -0.32Source |
| Earnings Per Share, DilutedUSD per share | -0.12Source | -0.26Source | -0.75Source | -0.32Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 9,026,130Source | 8,167,244Source | 7,747,686Source | 7,745,122Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 9,026,130Source | 8,167,244Source | 7,747,686Source | 7,745,122Source |
| Interest Expense (non-operating)USD | 493,384Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 19,104Source | 19,104Source | 19,104Source | 19,104Source |
| Current Income Tax Expense (Benefit)USD | — | 10,056Source | 4,627Source | 7,672Source |
| General and Administrative ExpenseUSD | 3,200,643Source | 2,216,549Source | 2,134,295Source | 2,263,817Source |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Gross ProfitUSD | 11,445,203Source | 7,941,044Source | 3,869,284Source | 7,648,779Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -1,028,457Source | — | — | — |
| Interest ExpenseUSD | — | — | 475,598Source | 348,536Source |
| Interest Income, OtherUSD | — | 77,702Source | 96,570Source | 153,100Source |
| Interest Revenue (Expense), NetUSD | — | -568,725Source | — | — |
| Investment Income, InterestUSD | 158,709Source | — | — | — |
| Nonoperating Income (Expense)USD | -2,677,762Source | -506,414Source | — | — |
| Operating ExpensesUSD | 9,795,898Source | 9,581,203Source | 9,617,362Source | 9,947,722Source |
| Other Cost of Operating RevenueUSD | — | — | — | 149,176Source |
| Other IncomeUSD | 3,776Source | — | 107Source | 912Source |
| Other Operating Income (Expense), NetUSD | — | — | — | 187,190Source |
| Research and Development ExpenseUSD | 3,041,880Source | 3,898,582Source | 4,394,852Source | 4,493,872Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 26,493,169Source | 17,471,669Source | 18,567,962Source |
| Selling and Marketing ExpenseUSD | 3,553,375Source | 3,466,072Source | 3,088,215Source | 3,190,033Source |
Filing attachments
ea025326501ex99-1_immucell.htm · 8-K · 2025-08-14
EX-99.1 2 ea025326501ex99-1_immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED AUGUST 14, 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 For Immediate Release PORTLAND, Maine - August 14, 2025 - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of…
Read attachment ↗ea025289001ex99-1_immucell.htm · 8-K · 2025-08-12
EX-99.1 4 ea025289001ex99-1_immucell.htm PRESS RELEASE OF THE COMPANY DATED AUGUST 12, 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Bank Debt Refinancing For Immediate Release PORTLAND, Maine - August 12, 2025 - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced it has succe…
Read attachment ↗ea024834701ex99-1_immucell.htm · 8-K · 2025-07-09
EX-99.1 2 ea024834701ex99-1_immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED JULY 9, 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 For Immediate Release PORTLAND, Maine - July 9, 2025 - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cat…
Read attachment ↗ea024700601ex99-1_immucell.htm · 8-K · 2025-06-25
EX-99.1 2 ea024700601ex99-1_immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED JUNE 25, 2025 Exhibit 99.1 ImmuCell ImmuCell Embarks on CEO Succession Planning Process For Immediate Release PORTLAND, Maine - June 25, 2025 - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announ…
Read attachment ↗ea024194301ex99-1_immucell.htm · 8-K · 2025-05-14
EX-99.1 2 ea024194301ex99-1_immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED MAY 14, 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025 For Immediate Release PORTLAND, Maine - May 14, 2025 - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dair…
Read attachment ↗ea023755201ex99-1_immucell.htm · 8-K · 2025-04-08
EX-99.1 2 ea023755201ex99-1_immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED APRIL 8, 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 For Immediate Release PORTLAND, Maine - April 8, 2025 - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef c…
Read attachment ↗